Boston Scientific Corporation (NYSE:BSX) Shares Bought by Illinois Municipal Retirement Fund

Illinois Municipal Retirement Fund boosted its stake in Boston Scientific Corporation (NYSE:BSX - Free Report) by 17.5% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 217,158 shares of the medical equipment provider's stock after acquiring an additional 32,356 shares during the period. Illinois Municipal Retirement Fund's holdings in Boston Scientific were worth $21,907,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Investment Management Corp VA ADV purchased a new stake in shares of Boston Scientific in the 4th quarter valued at about $25,000. Colonial Trust Co SC increased its position in Boston Scientific by 1,625.0% during the fourth quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock worth $25,000 after buying an additional 260 shares during the period. Sunbeam Capital Management LLC purchased a new stake in Boston Scientific in the fourth quarter valued at approximately $26,000. Ameriflex Group Inc. acquired a new stake in shares of Boston Scientific in the fourth quarter valued at approximately $31,000. Finally, Fairway Wealth LLC purchased a new stake in Boston Scientific in the 4th quarter valued at $36,000. Institutional investors and hedge funds own 89.07% of the company's stock.

Wall Street Analyst Weigh In

BSX has been the topic of a number of recent research reports. BTIG Research restated a "buy" rating and issued a $124.00 price objective on shares of Boston Scientific in a research note on Wednesday, April 23rd. Morgan Stanley boosted their price target on Boston Scientific from $120.00 to $125.00 and gave the company an "overweight" rating in a research report on Friday, May 16th. Truist Financial upped their price objective on Boston Scientific from $113.00 to $117.00 and gave the company a "buy" rating in a research note on Thursday, April 24th. Citigroup reiterated a "buy" rating and issued a $125.00 target price (up from $119.00) on shares of Boston Scientific in a research note on Thursday, May 22nd. Finally, Robert W. Baird boosted their target price on Boston Scientific from $115.00 to $120.00 and gave the company an "outperform" rating in a report on Thursday, April 24th. Twenty-two equities research analysts have rated the stock with a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat, Boston Scientific presently has a consensus rating of "Buy" and an average price target of $116.09.

Insider Buying and Selling

In other news, SVP Vance R. Brown sold 4,826 shares of the business's stock in a transaction on Monday, April 21st. The shares were sold at an average price of $95.09, for a total transaction of $458,904.34. Following the completion of the sale, the senior vice president now directly owns 36,193 shares of the company's stock, valued at $3,441,592.37. The trade was a 11.77% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Arthur C. Butcher sold 17,314 shares of the company's stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $102.06, for a total value of $1,767,066.84. Following the sale, the executive vice president now owns 22,235 shares of the company's stock, valued at approximately $2,269,304.10. The trade was a 43.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 411,970 shares of company stock valued at $42,406,693. Insiders own 0.50% of the company's stock.

Boston Scientific Trading Up 2.1%

Shares of NYSE:BSX traded up $2.25 during midday trading on Friday, reaching $106.83. The company's stock had a trading volume of 15,636,958 shares, compared to its average volume of 6,618,186. The firm has a market cap of $158.05 billion, a price-to-earnings ratio of 77.98, a price-to-earnings-growth ratio of 2.70 and a beta of 0.68. The business has a 50 day moving average price of $102.51 and a 200 day moving average price of $99.44. Boston Scientific Corporation has a 1 year low of $71.88 and a 1 year high of $107.17. The company has a quick ratio of 0.88, a current ratio of 1.45 and a debt-to-equity ratio of 0.47.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.67 by $0.08. The firm had revenue of $4.66 billion for the quarter, compared to analyst estimates of $4.57 billion. Boston Scientific had a return on equity of 18.67% and a net margin of 11.58%. The firm's quarterly revenue was up 20.9% on a year-over-year basis. During the same period last year, the company earned $0.56 EPS. Research analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.